News

October 05, 2022

TD2 Announces Dr. Alan Miller as New Chief Medical Officer

The respected Medical Oncology leader brings extensive experience as TD2 continues its strategic growth. SCOTTSDALE, ARIZONA, UNITED STATES, October 5, 2022 /EINPresswire.com/ -- Translational Drug Development (TD2), a precision oncology contract research organization (CRO), announces the addition of Dr. Alan...

August 25, 2022

SELLAS Life Sciences’ Highly Selective CDK9 Inhibitor, GFH009, Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Model of Neuroendocrine Prostate Cancer Cell Line

NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced...

August 09, 2022

SELLAS Life Sciences’ GFH009 Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Studies in Solid Cancer and Acute Myeloid Leukemia Cell Lines

NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) – SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced...

May 12, 2022

Genzada Pharmaceuticals Opens Phase 1B Metastatic Breast Cancer Trial

HUTCHINSON, Kan. – May 12, 2022 – Genzada Pharmaceuticals USA Inc. (Genzada), a subsidiary of Ionics Pharmaceuticals SA, announced today the official opening of a Phase 1B clinical trial for the oral therapeutic GZ17-6.02 (6.02) in combination with capecitabine in...

April 05, 2022

TD2 to Highlight Preclinical Progress of Two Novel HDAC Inhibitors at AACR Annual Meeting

SCOTTSDALE, ARIZONA, UNITED STATES, April 5, 2022 /EINPresswire.com/ -- Translational Drug Development (TD2), a precision oncology contract research organization (CRO), announces the presentation of the preclinical results of two novel, targeted epigenetic inhibitors at the American Association for Cancer Research...

March 30, 2022

Qualigen Therapeutics Engages TD2 as Contract Research Organization for Preclinical Development of QN-302

CARLSBAD, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces it...

October 14, 2021

TD2 Partners with Medidata to Enhance its Clinical Operations and Accelerate Clinical Trials

Medidata, a Dassault Systèmes company, today announced that Translational Drug Development (TD2), a precision oncology contract research organization (CRO), has signed an agreement to adopt Medidata’s Rave CTMS (Clinical Trial Management System) and eTMF (electronic Trial Master File) solutions. Rave CTMS and eTMF are...

September 16, 2021

TD2 and Deep Lens Partner to Enable Diversity, Access and Faster Clinical Trial Enrollment for Community Oncology Practices

Key Partnership Will Connect Patients with Precision Oncology Clinical Trials and Novel Therapies, Accelerating Access to Promising Treatments Translational Drug Development (TD2), a leading precision oncology contract research organization (CRO), and Deep Lens have announced a strategic partnership that will...

November 24, 2020

Laidlaw Venture Partners Portfolio Company Voltron Therapeutics Enters into Strategic Development Agreement With Translational Drug Development (TD2), a Precision Oncology Contract Research Organization (CRO)

The Companies Plan to Focus On Voltron’s VaxCelerate Vaccine Platform’s Effectiveness and Utility in a Variety of Tumor Settings Laidlaw Venture Partners (“LVP”), the venture capital arm of Laidlaw & Company (UK) Ltd., today announced a strategic development agreement with Translational...

October 29, 2020

TD2 and VieCure Partner to Bring Best-in-Class Cancer Medicines and Access to Precision Oncology Clinical Trials to Patients in Community Oncology Practices

Partnership Will Accelerate the Awareness and Adoption of Precision Oncology in Private Practices and Community Oncology Cancer Centers in the United States Translational Drug Development (TD2), a precision oncology contract research organization (CRO), and VieCure have announced a strategic partnership...

Load More

Events

March 14, 2023

4th Glioblastoma Drug Development Summit

Boston, MA | Hyatt Regency

Learn more +

March 31, 2023

Global Oncology Site Solutions Summit

Austin, TX | Hilton Austin

Learn more +

April 25, 2023

Clinical Operations In Oncology Trials: West Coast 2023

San Francisco, CA | San Francisco Airport Marriott Waterfront

Learn more +

STAY IN TOUCH

Get free tips, tools and resources by subscribing to the TD2 newsletter.

Skip to content